| Marylynn Cardona, MD | |
|
4403 Harrison Blvd, Ste 4650, Ogden, UT 84403-3271 | |
| (801) 475-3240 | |
| (801) 475-3241 |
| Full Name | Marylynn Cardona |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 4403 Harrison Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376703710 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 7780693-1205 (Utah) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
BioDelivery Sciences International, Inc. has filed its Annual Report with the U.S. Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2009. Such Form 10-K is available on the SEC's website at www.sec.gov.
Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.
ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, hosted the Novel Medical Imaging Approaches for Early Drug Development Methods, Technical Issues and Case Studies event, which took place at the Boston Marriott Cambridge, in Cambridge Massachusetts, on September 16, 2010.
Sedation is frequently required for mechanically ventilated intensive care unit (ICU) patients to reduce anxiety, provide comfort, and assist in providing optimal respiratory support.
New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marylynn Cardona, MD 4650 Harrison Blvd, Ogden, UT 84403-4303 Ph: (801) 475-3000 | Marylynn Cardona, MD 4403 Harrison Blvd, Ste 4650, Ogden, UT 84403-3271 Ph: (801) 475-3240 |
News Archive
BioDelivery Sciences International, Inc. has filed its Annual Report with the U.S. Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2009. Such Form 10-K is available on the SEC's website at www.sec.gov.
Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.
ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, hosted the Novel Medical Imaging Approaches for Early Drug Development Methods, Technical Issues and Case Studies event, which took place at the Boston Marriott Cambridge, in Cambridge Massachusetts, on September 16, 2010.
Sedation is frequently required for mechanically ventilated intensive care unit (ICU) patients to reduce anxiety, provide comfort, and assist in providing optimal respiratory support.
New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.
› Verified 7 days ago
Wesley Boyd Davis, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1525 E 6000 S, Ogden, UT 84405 Phone: 801-337-5800 Fax: 801-337-5809 | |
Dr. Sara Elizabeth Wood, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd, Ste 4815, Ogden, UT 84403 Phone: 801-387-8350 Fax: 801-387-8355 | |
Dr. Azadeh E Poursaid, MD, PHD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1525 E 6000 S Ste A, Ogden, UT 84405 Phone: 801-337-5800 Fax: 801-337-5809 | |
Dr. John David Lesser Ii, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Suite 4650, Ogden, UT 84403 Phone: 801-387-4400 Fax: 801-387-4410 | |
Dr. Steve F Johnson, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4647 Madison Ave, Ogden, UT 84403 Phone: 801-479-1537 | |
Dr. Rodney Stephen Merrill, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 434 E 5350 S, Suite A, Ogden, UT 84405 Phone: 801-479-1641 Fax: 801-476-8538 | |
Alexander J Larson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5495 S 500 E, Ste 310, Ogden, UT 84405 Phone: 801-475-3100 Fax: 801-475-3101 |